E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Parkinson's disease dyskinesia |
|
E.1.1.1 | Medical condition in easily understood language |
Parkinson's disease dyskinesia refers to a group of involuntary movement disorders. Dyskinesia can be anything from a slight tremor of the handds to an uncontrollable movement of the body. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10061536 |
E.1.2 | Term | Parkinson's disease |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
•To evaluate the effectiveness of adjunctive treatment with mesdopetam dosed at 2.5 mg, 5 mg or 7.5 mg b.i.d. (permitting a single 2.5 mg dose reduction to a minimum dose of 2.5 mg, up to Day 28) compared to placebo in patients with PD exhibiting troublesome ON-phase dyskinesia. |
|
E.2.2 | Secondary objectives of the trial |
•To establish the dose response relationship with 3 dose levels of mesdopetam. •To evaluate the effects of mesdopetam on severity of ON-phase dyskinesia and motor symptoms of PD. •To evaluate the effects of mesdopetam on the daily hours spent in different motor states. •To evaluate the safety and tolerability of mesdopetam given twice daily during 84 consecutive days. •To evaluate trough and 2-hour post dose plasma concentrations of mesdopetam and its two main metabolites, IRL902 (N-dealkylated) and IRL872 (acetylated).
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Male or female ≥30 and ≤79 years of age at the time of screening. 2.Signed a current Ethics Committee approved informed consent form (ICF). 3.PD, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria. 4.Minimal amount of 2 hours of daily “ON-time with troublesome dyskinesia” during waking hours. 5.Functional impact of dyskinesias determined as a score of ≥2 as per Question 4.2 of the MDS-UPDRS. 6.On a stable regimen of antiparkinson medications for at least 30 days prior to first home diary completion including a levodopa preparation administered 3-8 times/day (excluding nighttime levodopa) and willing to continue the same doses and regimens during study participation. Rescue medications such as Madopar dispersable and Apomorphine injections are allowed if prescribed PRN prior study entry. 7.Any other current and allowed prescription/non-prescription medications and/or nutritional supplements taken regularly must have been at a stable dose and regimen for at least 30 days prior to first home diary completion and the patient must be willing to continue the same doses and regimens during study participation (this criterion does not apply to medications that are being taken pre-study only on an as-needed basis). 8.Able to complete 24-hour patient home diaries of which two valid diaries must be presented at Visit 1. |
|
E.4 | Principal exclusion criteria |
1.History of neurosurgical intervention related to PD (e.g. deep brain stimulation). 2.Treatment with pump delivered antiparkinsonian therapy (i.e. subcutaneous apomorphine or levodopa/carbidopa intestinal infusion). 3.History of seizures within two years prior to screening. 4.History of stroke or transient ischemic attack (TIA) within two years prior to screening. 5.History of cancer within five years prior to screening, with the following exceptions: adequately treated non-melanomatous skin cancers, localized bladder cancer, non metastatic prostate cancer or in situ cervical cancer. 6.Presence of cognitive impairment, as evidenced by a Mini-Mental State Examination (MMSE) score of less than 24 during screening. 7.A Hoehn and Yahr stage of 5. 8.Ongoing treatment with amantadine at time of screening or within 6 weeks prior first home diary completion. 9.Treatment with Inbrija (inhaled levodopa) at time of screening or within 4 weeks prior first home diary completion. 10.Any history of a significant heart condition or cardiac arrhythmias within the past 5 years, any repolarisation deficits or any other clinically significant abnormal ECG as judged by the Investigator. 11.Severe or ongoing unstable medical condition including a history of poorly controlled diabetes; obesity associated with metabolic syndrome; uncontrolled hypertension; cerebrovascular disease, or any form of clinically significant cardiac disease, clinically significant symptomatic orthostatic hypotension; clinically significant hepatic disease, severe renal impairment, i.e. creatinine clearance <30 mL/min. 12.Any history of a neurological other than PD or a psychiatric disorder, including history of Diagnostic and Statistical Manual of Mental Disorders (DSM) IV diagnosed major depression or psychosis. Patients with illusions or hallucinations with no loss of insight will be eligible. Patients with mild depression who are well controlled on a stable dose of an antidepressant medication for at least 4 weeks before screening will be eligible. 13.Enrolment in any other clinical study involving medication, medical devices or surgical procedures, current or within three months prior to screening visit, or previous participation in the present study. Patients enrolled in non-interventional clinical trials will be eligible. 14.Drug and/or alcohol abuse. 15.History of severe drug allergy or hypersensitivity. 16.If female, is pregnant or lactating, or has a positive pregnancy test result pre-dose. 17.Patients unwilling to use two forms of contraception (one of which being a barrier method (see Section 8.1) during the treatment period and 90 days for men and 30 days for women after last IMP dose. 18.Any planned major surgery within the duration of the study. 19.Any other condition or symptoms preventing the patient from entering the study, according to the Investigator’s judgement. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change in average daily hours of ON-time without troublesome dyskinesia with mesdopetam compared to placebo as assessed with 24-hour patient home diaries from baseline to end of treatment (EOT) (Visit 5, Week 12). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Change from baseline in average daily hours of ON-time without troublesome dyskinesia for each individual dose level (2.5 mg, 5 mg, 7.5 mg b.i.d.), as well as all active doses grouped compared to placebo. • Change from baseline in mean score or average daily hours with mesdopetam compared to placebo for the following measures: - ON-phase dyskinesia assessed with the sum score of the modified UDysRS (parts 1, 3 and 4). - Disability associated with ON-phase dyskinesia assessed with the sum score of parts 1b and 4 of the UDysRS. - ON-phase dyskinesia assessed by MDS-UPDRS part 4 questions 4.1 (Time spent with dyskinesias) and 4.2 (Functional impact of dyskinesias). - Motor symptoms of PD assessed with MDS-UPDRS total score of part 2 (M-EDL). - Daily OFF-time, daily ON-time with troublesome dyskinesia and daily total ON time (defined as the sum of ON-time with and without troublesome dyskinesia). - CGI-S of ON-phase dyskinesia. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 14 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
France |
Israel |
Italy |
Poland |
Serbia |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 4 |